CETUXIMAB, CISPLATIN, AND IRINOTECAN IN TREATING PATIENTS WITH METASTATIC ESOPHAGEAL CANCER, GASTROESOPHAGEAL JUNCTION CANCER, OR GASTRIC CANCER THAT DID NOT RESPOND TO PREVIOUS IRINOTECAN AND CISPLATIN: